A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

Nature Medicine

Volumn 8, Issue 12, 2002, Pages 1369-1375

  Niethammer, Andreas G ^a   Xiang, Rong ^a   Becker, Jurgen C ^b   Wodrich, Harald ^a   Pertl, Ursula ^a   Karsten, Gabriele ^a   Eliceir, Brian P ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DNA VACCINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER INHIBITION; CANCER PREVENTION; COLON CARCINOMA; ENDOTHELIUM; ENDOTHELIUM CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LUNG CARCINOMA; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VASCULARIZATION; VACCINATION; WOUND HEALING;

ANIMALIA;

EID: 0036913333     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1202-794     Document Type: Article

References (37)

1. Folkman, J. Addressing tumor blood vessels. Nature Biotechnol. 15, 510 (1997).
2. Folkman, J. Angiogenesis and angiogenesis inhibition: An overview. EXS 79, 1-8 (1997).
3. Folkman, J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95, 9064-9066 (1998).
4. O'Reilly, M.S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996)
5. O'Reilly, M.S. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
6. Augustin, H.G. Antiangiogenic tumor therapy: Will it work? Trends Pharmacol. Sci. 19, 216-222 (1998).
7. Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393 (2000).
8. Folkman, J. Tumor angiogenesis and tissue factor. Nature Med. 2, 167-168 (1996).
9. Goede, V. et al. Prognostic value of angiogenesis in mammary tumors. Anticancer Res. 18, 2199-2202 (1998).
10. Folkman, J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc. Natl. Acad. Sci. USA 98, 398-400 (2001).
11. Heidenreich, R., Kappel, A. & Breier, G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (FLK-1) promoter/enhancer sequences. Cancer Res. 60, 6142-6147 (2000).
12. Hicklin, D.J., Marincola, F.M. & Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186 (1999).
13. Ruiter, D.J., Mattijssen, V., Broecker, E.B. & Ferrone, S. MHC antigens in human melanomas. Semin. Cancer Biol. 2, 35-45 (1991).
14. Cheng, W.F. et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108, 669-678 (2001).
15. Wei, Y.Q. et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nature Med. 6, 1160-1166 (2000).
16. Kisker, O. et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61, 7669-7674 (2001).
17. Cross, M.J. & Claesson-Welsh, L. FGF and VEGF function in angiogenesis: Signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22, 201-207 (2001).
18. Dias, S. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521 (2000).
19. Drake, C.J., LaRue, A., Ferrara, N. & Little, C.D. VEGF regulates cell behavior during vasculogenesis. Dev. Biol. 224, 178-188 (2000).
20. Ferrara, N. VEGF: An update on biological and therapeutic aspects. Curr. Opin. Biotechnol. 11, 617-624 (2000).
21. Folkman, J. & D'Amore, P.A. Blood vessel formation: What is its molecular basis? Cell 87, 1153-1155 (1996).
22. McMahon, G. VEGF receptor signaling in tumor angiogenesis. Oncologist 5 Suppl 1, 3-10 (2000).
23. Ortega, N., Hutchings, H. & Plouet, I. Signal relays in the VEGF system. Front Biosci. 4, D141-D152 (1999).
24. Strawn, L.M. et al. FLK-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545 (1996).
25. Taraboletti, G. & Margosio, B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. 1, 378-384 (2001).
26. Ochsenbein, A.F. et al. Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
27. Hata, Y., Rook, S.L. & Aiello, L.P. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 48, 1145-1155 (1999).
28. St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
29. Niethammer, A.G. et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 20, 421-429 (2001).
30. Niethammer, A.G. et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res. 61, 6178-6184 (2001).
31. Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775 (1997).
32. Lode, H.N. et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. USA 95, 2475-2480 (1998).
33. Schrama, D. et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14, 111-121 (2001).
34. Kaesler, S., Regenbogen, J., Durka, S., Goppelt, A. & Werner, S. The healing skin wound: A novel site of action of the chemokine c10. Cytokine 17, 157-163 (2002).
35. Werner, S. et al. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl. Acad. Sci. USA 89, 6896-6900 (1992).
36. Barlow, C. et al. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86, 159-171 (1996).
37. Paylor, R. et al. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: A behavioral characterization of Acra7-deficient mice. Learn. Mem. 5, 302-316 (1998).